Drug delivery vehicle

Abstract

The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.

1 - 67 . (canceled) 
     
     
         68 . A targeted drug delivery vehicle comprising:
 a drug composition and 5-50 of a targeted poly-amino-acid subunit,   wherein the targeted poly-amino-acid subunit comprises a targeting amino acid chain conjugated to a fatty acid, and   wherein the targeting amino acid chain is 15-20 amino acids of an apolipoprotein A-1 and binds to a SR-B1 receptor.   
     
     
         69 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18, 19, 20, 21, 22, 23, 24, 25, or 26. 
     
     
         70 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 27, 28, 29, 30, 31, 32, 33, or 34. 
     
     
         71 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 35, 36, 37, 38, 39, 40, 41, or 42. 
     
     
         72 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 43, 44, 45, 46, 47, 48, 49, 50, or 51. 
     
     
         73 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 52, 53, 54, 55, 56, 57, 58, or 59. 
     
     
         74 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 60, 61, 62, 63, 64, 65, or 66. 
     
     
         75 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid chain is 1-15 carbons in length. 
     
     
         76 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid chain is a myristic acid. 
     
     
         77 . The target drug delivery vehicle of  claim 68 , wherein targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid is an unesterified cholesterol. 
     
     
         78 . The target drug delivery vehicle of  claim 68 , wherein targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid is a palmitoyl-oleyl phosphatidylcholine. 
     
     
         79 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid is a phospholipid. 
     
     
         80 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid is a saturated fatty acid. 
     
     
         81 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain and the fatty acid are in a ratio of 1:1. 
     
     
         82 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is covalently linked to the fatty acid. 
     
     
         83 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain comprises one or more amphipathic alpha-helical domains. 
     
     
         84 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has affinity to a transmembrane molecule. 
     
     
         85 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has affinity to a receptor. 
     
     
         86 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has affinity to an HDL receptor. 
     
     
         87 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has affinity to rapidly dividing cells. 
     
     
         88 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has enhanced affinity to a cancer cell. 
     
     
         89 . The target drug delivery vehicle of  claim 68 , wherein the targeted drug delivery vehicle does not comprise an unesterified cholesterol, a cholesteryl ester, a phospholipid, selected from the group consisting of: a phosphatidylcholine, a phosphatidylserine, a phosphatidylethanolamine, a phosphatidylinositol, a sphingomyelin, and an apolipoprotein A-1 protein. 
     
     
         90 . The target drug delivery vehicle of  claim 68 , wherein the targeted drug delivery vehicle further comprises one or more compounds selected from the group consisting of: an unesterified cholesterol, a palmitoyl-oleoyl phosphatidylcholine, a phospholipid, an apolipoprotein A-1 protein, and a 15-20 amino acid chain of an apolipoprotein A-1 and binds to a SR-B1 receptor. 
     
     
         91 . The target drug delivery vehicle of  claim 68 , wherein the targeted drug delivery vehicle has a diameter of about 20-300 nm. 
     
     
         92 . The target drug delivery vehicle of  claim 68 , wherein the drug composition has a greater solubility than a drug alone. 
     
     
         93 . The target drug delivery vehicle of  claim 68 , wherein the drug composition comprises a hydrophobic drug, a cytotoxic drug, an antibody drug, a protein or peptide drug, a mimetic peptide drug, a gene drug, a vaccine drug, or any combination or salt thereof. 
     
     
         94 . The target drug delivery vehicle of  claim 68 , wherein the targeted drug delivery vehicle has a % payload recovery that is greater than 30%. 
     
     
         95 . The target drug delivery vehicle of  claim 68 , wherein after administration in a body fluid of a subject, the targeted drug delivery vehicle maintains greater than 80% of the original drug concentration. 
     
     
         96 . The target drug delivery vehicle of  claim 68 , wherein the targeted drug delivery vehicle increases a therapeutic index greater than 60% than a drug alone. 
     
     
         97 . The target drug delivery vehicle of  claim 68 , wherein the targeted drug delivery vehicle increases a therapeutic index at least 10% greater than a drug alone. 
     
     
         98 . The target drug delivery vehicle of  claim 68 , wherein the drug alone is a free drug. 
     
     
         99 . The target drug delivery vehicle of  claim 68 , wherein the drug alone comprises an albumin or a nonionic surfactant. 
     
     
         100 . The target drug delivery vehicle of  claim 99 , wherein the nonionic surfactant is a polyoxyl castor oil (Cremophor EL™). 
     
     
         101 . The target drug delivery vehicle of  claim 68 , wherein after administration to a subject, the subject's blood contains less than 10% of the drug composition as than a free drug alone. 
     
     
         102 . A targeted drug delivery vehicle comprising:
 a drug composition and 5-50 of a targeted poly-amino-acid subunit,   wherein the targeted poly-amino-acid subunit comprises a polynucleotide drug composition, a phospholipid, an excipient, and a targeting amino acid chain, and   wherein the targeting amino acid chain is 15-20 amino acids of an apolipoprotein A-1 and binds to the SR-B1 receptor.   
     
     
         103 . The targeted drug delivery vehicle of  claim 102 , wherein the targeting amino acid chain is SEQ ID NOs.: 18, 19, 20, 21, 22, 23, 24, 25, or 26. 
     
     
         104 . The targeted drug delivery vehicle of claim  1022 , wherein the targeting amino acid chain is SEQ ID NOs.: 27, 28, 29, 30, 31, 32, 33, or 34. 
     
     
         105 . The targeted drug delivery vehicle of claim  1022 , wherein the targeting amino acid chain is SEQ ID NOs.: 35, 36, 37, 38, 39, 40, 41, or 42. 
     
     
         106 . The targeted drug delivery vehicle of claim  1022 , wherein the targeting amino acid chain is SEQ ID NOs.: 43, 44, 45, 46, 47, 48, 49, 50, or 51. 
     
     
         107 . The targeted drug delivery vehicle of  claim 102 , wherein the targeting amino acid chain is SEQ ID NOs.: 52, 53, 54, 55, 56, 57, 58, or 59. 
     
     
         108 . The targeted drug delivery vehicle of claim  1022 , wherein the targeting amino acid chain is SEQ ID NOs.: 60, 61, 62, 63, 64, 65, or 66. 
     
     
         109 . The targeted drug delivery vehicle of claim  1022 , wherein the polynucleotide drug composition is in the range of about 4-200 nucleotide base pairs. 
     
     
         110 . The targeted drug delivery vehicle of claim  1022 , wherein the phospholipid is phosphatidylcholine. 
     
     
         111 . The targeted drug delivery vehicle of claim  1022 , wherein the targeted drug delivery vehicle has a diameter of about 300 nm to 1000 nm. 
     
     
         112 . The targeted drug delivery vehicle of claim  1022 , wherein the polynucleotide drug composition is neutralized before encapsulation into the targeted drug delivery vehicle. 
     
     
         113 . The targeted drug delivery vehicle of claim  1022 , wherein polynucleotide drug composition has enhanced bioavailability than a polynucleotide drug alone. 
     
     
         114 . The targeted drug delivery vehicle of claim  1022 , wherein the polynucleotide drug composition has enhanced therapeutic benefits than a polynucleotide drug alone.